|
Orthocell receives A$3.17m R&D tax incentive refund
|
21 June 2023 at 9:25am
|
|
Change of Director's Interest Notice - Paul Anderson
|
16 June 2023 at 9:30am
|
|
Change of Director's Interest Notice - Paul Anderson
|
13 June 2023 at 9:55am
|
|
Initial Director's Interest Notice - John Van Der Wielen
|
1 June 2023 at 4:40pm
|
|
Proposed issue of securities - OCC
|
29 May 2023 at 10:10am
|
|
Notification regarding unquoted securities - OCC
|
29 May 2023 at 10:10am
|
|
John Van Der Wielen appointed Independent Non-Exec Chair
|
29 May 2023 at 9:35am
|
|
Option Terms and Conditions
|
26 May 2023 at 8:55am
|
|
Notification regarding unquoted securities - OCC
|
26 May 2023 at 8:50am
|
|
Quarterly Activity Report & Appendix 4C
|
27 April 2023 at 9:25am
|
|
Cleansing Notice
|
19 April 2023 at 2:00pm
|
|
Application for quotation of securities - OCC
|
19 April 2023 at 1:50pm
|
|
Notification regarding unquoted securities - OCC
|
19 April 2023 at 1:50pm
|
|
Orthocell commences nerve repair study
|
18 April 2023 at 9:25am
|
|
Leading US-based nerve surgeons appointed to advisory board
|
29 March 2023 at 9:35am
|
|
Initial Director's Interest Notice-RT
|
8 March 2023 at 2:40pm
|
|
Notification regarding unquoted securities - OCC
|
8 March 2023 at 2:30pm
|
|
Orthocell Appoints Non-Executive Director Dr Ravi Thadhani
|
8 March 2023 at 9:40am
|
|
Orthocell appoints Company Secretary Mr Peter Webse
|
1 March 2023 at 10:20am
|
|
Half Yearly Report and Accounts
|
28 February 2023 at 6:35pm
|
|
Investor Presentation
|
2 February 2023 at 10:20am
|
|
Appendix 4C - Quarterly
|
30 January 2023 at 1:40pm
|
|
Change of Director's Interest Notice PA
|
23 November 2022 at 9:30am
|
|
Change of Director's Interest Notice LL
|
23 November 2022 at 9:30am
|
|
Notification of cessation of securities - OCC
|
23 November 2022 at 9:25am
|
|
Notification of cessation of securities - OCC
|
23 November 2022 at 9:25am
|
|
Change of Director's Interest Notice LL Revised
|
11 November 2022 at 11:20am
|
|
Change of Director's Interest Notice LL
|
9 November 2022 at 9:35am
|
|
Remplir Gains Australian Reimbursement
|
1 November 2022 at 9:40am
|
|
Appendix 4C - Quarterly
|
31 October 2022 at 6:45pm
|
|
Results of Meeting
|
28 October 2022 at 3:05pm
|
|
Investor Presentation
|
26 October 2022 at 10:10am
|
|
OrthoATI Rotator Cuff Study Success With Cross-Over Patients
|
29 September 2022 at 9:00am
|
|
Letter to Shareholders - Annual General Meeting
|
28 September 2022 at 12:20pm
|
|
Notice of Annual General Meeting/Proxy Form
|
28 September 2022 at 12:20pm
|
|
First orders for Striate and Remplir
|
27 September 2022 at 9:25am
|
|
Appointment of Exclusive Australian Distributor for Remplir
|
7 September 2022 at 10:25am
|
|
Trading Halt
|
6 September 2022 at 9:45am
|
|
Annual General Meeting
|
5 September 2022 at 5:20pm
|
|
Appendix 4G
|
31 August 2022 at 10:10am
|
|
Final Report and Annual Report to Shareholders
|
31 August 2022 at 9:00am
|
|
Notice under Section 708(A) of the Corporations Act
|
17 August 2022 at 7:30pm
|
|
Notification of cessation of securities - OCC
|
17 August 2022 at 7:25pm
|
|
Application for quotation of securities - OCC
|
17 August 2022 at 7:25pm
|
|
Appendix 4C - Quarterly
|
29 July 2022 at 12:30pm
|
|
Updated Investor Presentation
|
27 July 2022 at 10:20am
|
|
Striate Global License and Distribution Agreement Update
|
21 July 2022 at 9:40am
|
|
Option Terms and Conditions
|
15 July 2022 at 7:25pm
|
|
Notification regarding unquoted securities - OCC
|
14 July 2022 at 9:50am
|
|
Notification regarding unquoted securities - OCC
|
14 July 2022 at 9:30am
|
Orthocell